๐ข ๐๐๐๐ ๐๐: $ImmunityBio(IBRX.US) ImmunityBio Reports Favorable Bladder Cancer Data at ๐๐๐ ๐๐๐๐
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐๐๐๐๐๐ยฎ + BCG showed stronger complete response outcomes versus competitors.โค NAI+BCG patients were ๐ร more likely to achieve complete response versus nadofaragene.โค Median complete response duration reached ๐๐.๐ months versus ๐.๐ months.โค NAI+BCG reduced ๐๐ฒ๐ฌ๐ญ๐๐๐ญ๐จ๐ฆ๐ฒ risk by ๐๐% versus nadofaragene.โค Compared with TAR-200, NAI+BCG showed numerically higher ๐๐-๐ฆ๐จ๐ง๐ญ๐ก CR rates.โค NAI+BCG demonstrated significantly fewer ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ-๐ซ๐๐ฅ๐๐ญ๐๐ adverse events than TAR-200.โค Data presented at ๐๐๐ ๐๐๐๐ for BCG-unresponsive bladder cancer patients.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments